NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies
Here's what happens when the medicine heals your mind, but the body keeps the score long after. [...] Read More... The post Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies appeared first on...
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…
Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans
Veterans built the psychedelic policy movement in state legislatures. This year, firefighters, police officers, and EMTs joined them, and states once written off as unlikely are now leading. Logan Davidson traces the ...
The haunting of Shawn Ryan
The odd romance between ibogaine and the Christian right may be cracking
A study of about 21,800 people in two UK birth cohorts linked lifetime psilocybin or LSD use with pro-environmental attitudes and a greater likelihood of a vegetarian diet.
Teixeira et al. analysed two UK birth cohorts and found that lifetime classic psychedelic use was associated with more pro-environmental attitudes and higher odds of adopting a vegetarian diet. Psilocybin users report...
Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder
This preregistered secondary-analysis preprint (n=20) examined therapeutic relationships during an open-label MDMA-assisted therapy trial for social anxiety. Therapeutic alliance remained high, while perceived closene...
Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder
This preregistered secondary-analysis preprint (n=20) examined therapeutic relationships during an open-label MDMA-assisted therapy trial for social anxiety. Therapeutic alliance remained high, while perceived closene...
Wireless brain-recording device enables animal neuroscience experiments in natural habitats
A new wireless device—lighter than a U.S. dime and shaped like a tiny chef's hat—can track the brain waves of animals as they move in natural habitats, opening doors to understanding complex behaviors that are impossi...
THE GATEWAY: Live From DC After the FDA Psychedelics Hearing
Join us after the FDA’s September 14 psychedelics hearing for THE GATEWAY—an evening of networking, conversation, and a live podcast recording about what happened at FDA and what comes next.
Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its “new framework for psychedelic drugs”. The four agency staffers kick off the article by outlining the s...
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare…
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
NEW YORK, September 10, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to…
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
LONDON & NEW YORK, September 10, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
Compass Pathways to Participate in Investor Conferences the Week of September 14th
LONDON & NEW YORK, September 10, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today…
Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease
This rat study found that a single psilocybin dose (2.5 mg/kg) improved spatial memory and learning in a chemically induced model of Alzheimer's-like pathology. The behavioural improvements were not accompanied by con...